

S8 Table. Comparison of somatic CNV gain between patients with detectable and undetectable MRD

Gene	Detectable MRD			Undetectable MRD			p-value	OR
	Gain (n)	Wt (n)	Frequency (%)	Gain (n)	Wt (n)	Frequency (%)		
<i>ERBB2</i>	7	11	38.9	17	45	27.4	0.3886	1.673
<i>CDK12</i>	6	12	33.3	10	52	16.1	0.1767	2.564
<i>GATA3</i>	2	16	11.1	1	61	1.6	0.1254	7.368
<i>GNAS</i>	2	16	11.1	3	59	4.8	0.3131	2.425
<i>BRIP1</i>	3	15	16.7	2	60	3.2	0.0724	5.821
<i>CDKN2A</i>	2	16	11.1	0	62	0.0	0.0484	Inf
<i>HOXB13</i>	3	15	16.7	0	62	0.0	0.0099	Inf
<i>MYC</i>	3	15	16.7	16	46	25.8	0.5394	0.579
<i>PPM1D</i>	2	16	11.1	0	62	0.0	0.0484	Inf
<i>SPOP</i>	2	16	11.1	6	56	9.7	1	1.164
<i>EGFR</i>	2	16	11.1	2	60	3.2	0.2169	3.671
<i>KRAS</i>	2	16	11.1	2	60	3.2	0.2169	3.671
<i>MDM4</i>	2	16	11.1	3	59	4.8	0.3131	2.425
<i>MPL</i>	2	16	11.1	0	62	0.0	0.0484	Inf
<i>RAD51C</i>	2	16	11.1	2	60	3.2	0.2169	3.671
<i>VHL</i>	2	16	11.1	0	62	0.0	0.0484	Inf

CNV, copy number variant; MRD, molecular residual disease; OR, odds ratio.